The PFP products protect medicines from contamination. They include a combination of a formulation without chemical preservatives, a pump system that filters or blocks the returning air, and an actuator that prevents bacterial ingress into the dispenser.
MWV says the five-fold mechanical protection system assures germ-free pump dosing to the patient. It includes non-return valves next to the orifice bore and in the metering chamber, and a filter element for contamination-free ventilation of the container, a locked actuator, and a sealed air path during storage.
The PFP T delivers volumes from 0.05mL to 0.14mL. Upside down and tamper-evident features are also available with the product.
‘We are expanding the range of preservative free pumps to meet consumer demand for preservative-free formulations,’ said Chris Hall, vice president and managing director, Medical Plastics Division, MWV Healthcare.
‘This technology does more than protect preservative free medicines from contamination, it is also suitable for use with other topical or dermal products where protecting the formulation and maintaining sterility is important, and necessary.’
MWV Healthcare expands preservative free pumps line
Manufacturing facility awarded certification for PFP spray systems
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Drug Delivery
embecta completes £100m acquisition of UK-based Owen Mumford to bolster drug delivery portfolio
US diabetes care company embecta has finalised its acquisition of Owen Mumford, gaining access to the Aidaptus next-generation auto-injector platform as it accelerates its transition into a broad-based medical supplies company
Pharmaceutical
MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients
The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Drug Delivery
Wearable pumps and subcutaneous delivery: a new frontier in heart failure management
Two recent developments are reshaping how drug delivery technology can move treatment out of the clinic and into patients’ everyday lives — with implications for both formulation science and device manufacturing